Stephen G. Dilly, M.B.B.S., Ph.D. joined the Avigen board in 2007. He has served as CEO of APT Pharmaceuticals of Foster City, California since September 2006. He graduated as a physician from the University of London in 1982 and received his Ph.D. in Cardiac Physiology from University of London in 1988. Dr. Dilly began his industry career with Pfizer Central Research in the UK in 1986, and since then has held positions of increasing responsibility with Beecham, SmithKline Beecham (VP of CardioPulmonary, VP of Clinical Neuroscience), Genentech (Head of Clinical, Head of Development Sciences) and Chiron BioPharma (SVP Development, Chief Medical Officer). During this career, he has been closely associated with the successful development and launch of a number of important new drugs across many therapeutic areas including Kytril, Paxil CR, Kredex, Requip, TNKase, Xolair, Avastin, Raptiva, Tarceva, Lucentis and Cubicin.